THOMAS KOSTEN to Biomarkers
This is a "connection" page, showing publications THOMAS KOSTEN has written about Biomarkers.
Connection Strength
0.195
-
Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr Res. 2013 Feb; 143(2-3):301-6.
Score: 0.050
-
Association between the 5-HTR1B gene polymorphisms and alcohol dependence in a Han Chinese population. Brain Res. 2011 Feb 28; 1376:1-9.
Score: 0.044
-
The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res. 2009 Sep; 113(2-3):151-7.
Score: 0.039
-
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. Am J Addict. 2019 07; 28(4):311-317.
Score: 0.019
-
Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol Biol Psychiatry. 2018 07 13; 85:69-76.
Score: 0.018
-
Low BDNF is associated with cognitive deficits in patients with type 2 diabetes. Psychopharmacology (Berl). 2013 May; 227(1):93-100.
Score: 0.012
-
Decreased levels of serum brain-derived neurotrophic factor in drug-na?ve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl). 2009 Dec; 207(3):375-80.
Score: 0.010
-
Multidimensional hormonal discrimination of paranoid schizophrenic from bipolar manic patients. Biol Psychiatry. 1991 Mar 01; 29(5):457-66.
Score: 0.003